Gingivitis Market Report 2026

The gingivitis market size has grown steadily in recent years. It will grow from $7.45 billion in 2025 to $7.8 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to poor oral hygiene habits, growth in dental consultations, early adoption of antiseptic treatments, public health dental programs, rising sugar consumption.

The gingivitis market size is expected to see steady growth in the next few years. It will grow to $9.3 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to preventive dentistry adoption, expansion of oral care products, digital dental consultations, school-based oral health programs, rising healthcare literacy. Major trends in the forecast period include increased focus on preventive oral care, rising use of non-surgical treatments, growth in antibacterial oral care products, expansion of home-based oral hygiene solutions, improved public awareness of gum health.

The rising prevalence of gum disease is expected to drive the growth of the gingivitis market in the coming years. Gum disease is a common oral condition characterized by inflammation, infection, or deterioration of the gums and surrounding tissues, primarily caused by plaque accumulation and poor oral hygiene. The increasing occurrence of gum disease is largely attributed to inadequate oral care, which leads to plaque buildup and bacterial infections. Diets high in sugar and processed foods contribute to gum inflammation, while smoking compromises immune function, making gums more susceptible to infection. Gingivitis, as the earliest stage of gum disease, plays a significant role in its growing prevalence by acting as a precursor to more severe conditions like periodontitis if left untreated, highlighting the importance of early intervention and preventive care. For instance, in January 2024, a report by the Office for Health Improvement & Disparities (OHID), a UK-based government agency, noted that the proportion of adults diagnosed with gum disease increased from 4% among those aged 16-24 to 28% among individuals aged 55-64, demonstrating higher prevalence with age. Therefore, the rising prevalence of gum disease is driving the growth of the gingivitis market.

Major companies in the gingivitis market are developing innovative products such as formulated toothpaste to specifically target gum inflammation, reduce plaque accumulation, and promote overall oral health. Formulated toothpaste is specially designed with active ingredients to address targeted oral health concerns such as cavities, gingivitis, or tooth sensitivity. For instance, in February 2023, Frimline Private Limited, an India-based healthcare and personal care company, launched Dente91 She toothpaste. This toothpaste is enriched with lactoferrin, a potent antimicrobial protein that helps protect against oral infections and inflammation. Unlike conventional toothpaste, Dente91 She also contains folic acid (vitamin B9) and pyridoxine (vitamin B6) to support women’s oral health throughout hormonal changes from puberty to menopause.

In October 2024, Natural Dentist LLC, a US-based oral care company, acquired Caldwell Consumer Products, including brands such as The Natural Dentist, Stim-U-Dent, Fresh ‘n Brite, and EarthPicks, for an undisclosed amount. This acquisition aims to expand Natural Dentist LLC’s product portfolio, enhance supply chain efficiency, and drive innovation in holistic oral care solutions. Caldwell Consumer Health LLC is a US-based consumer healthcare company specializing in oral care and personal health products.

Major companies operating in the gingivitis market are Procter & Gamble, Colgate-Palmolive Company, Haleon group, Bausch Health Companies Inc., Kivonyx Healthcare Pvt Ltd., ICPA Health Products Limited, Alarsin Pharmaceuticals, Laboratorios KIN, Ikon remedies pvt ltd., Perio Protect LLC, Algen Healthcare Ltd, Neuracle Lifesciences Private Limited, Dental Herb Company, Shreeji Pharma International, Pfizer Inc., Johnson & Johnson, 3M Company, Dentsply Sirona Inc., Sunstar Group, GC Corporation, Ivoclar Vivadent AG, Straumann Group, Ultradent Products Inc, Nobel Biocare Holdings AG.

North America was the largest region in the gingivitis market in 2025. The regions covered in the gingivitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gingivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gingivitis market by increasing costs of imported dental medications, antiseptic products, and diagnostic tools. Dental clinics and pharmacies are most affected due to reliance on imported oral care products. These tariffs raise treatment costs by increasing pricing of prescription rinses, topical agents, and diagnostic consumables. However, they encourage local oral healthcare manufacturing, supporting domestic production of dental medications and hygiene products.

The gingivitis market research report is one of a series of new reports that provides gingivitis market statistics, including gingivitis industry global market size, regional shares, competitors with a gingivitis market share, detailed gingivitis market segments, market trends and opportunities, and any further data you may need to thrive in the gingivitis industry. This gingivitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gingivitis is a common, mild form of gum disease (periodontal disease) characterized by inflammation, redness, swelling, and bleeding of the gums, primarily due to plaque accumulation along the gumline. If left untreated, it can progress to more severe periodontal conditions, potentially causing gum recession and tooth loss.

The main treatment approaches for gingivitis include medications, surgical procedures, and non-surgical therapies. Medications for gingivitis consist of antimicrobial mouthwashes, antiseptic gels, and antibiotics, which help reduce inflammation, control bacterial growth, and promote gum healing. These treatments are administered through oral and topical routes and are distributed via retail pharmacies, hospital pharmacies, and online pharmacies. End users include hospitals, dental clinics, and home care settings.

The gingivitis market consists of revenues earned by entities providing services such as preventive dental care, periodontal therapy, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The gingivitis market also includes sales of toothpaste, mouthwashes, and interdental brushes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.